clinical trial · NCT04394546
CHAMPION-AF Clinical Trial
Atrial FibrillationStrokeBleedingWATCHMAN FLX LAAC DeviceNon-Vitamin K Oral Anticoagulant
brief summary
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
started
Oct 15, 2020
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Aug 12, 2026
detailed description
This study is a prospective, randomized, multi-center global investigation. Subjects will be randomized to either the WATCHMAN FLX Left Atrial Appendage Closure Device ("Device Group") or a commercially available non-vitamin K oral anticoagulant ("Control Group").
official title
WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol